Prelude Capital Management, LLC Spring Works Therapeutics, Inc. Transaction History

Prelude Capital Management, LLC

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2025 Aug 14, 2025	BUY	$34.43 - $46.99 $4.84 Million - $6.6 Million	140,533 Added 450.67%	171,716 $8.07 Million
Q1 2025 May 15, 2025	BUY	$32.5 - $59.93 $479,245 - $883,727	14,746 Added 89.71%	31,183 $1.38 Million
Q4 2024 Feb 14, 2025	SELL	$28.61 - $42.55 $802,682 - $1.19 Million	-28,056 Reduced 63.06%	16,437 $593,000
Q3 2024 Nov 14, 2024	BUY	$32.04 - $42.76 $898,914 - $1.2 Million	28,056 Added 170.69%	44,493 $1.43 Million
Q1 2024 May 15, 2024	BUY	$36.5 - $52.5 $99,864 - $143,640	2,736 Added 19.97%	16,437 $809,000

Q4 2023 Feb 14, 2024	BUY	$18.94 - $37.24 $259,496 - $510,225	13,701 New	13,701 $500,000

7.4M

23K

Ticker SWTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 62,401,100
Market Cap $2.93B
Description
SpringWorks Therapeutics, Inc. acquires, develops, and commercializes medicines for underserved patient populations suffering from rare diseases and cancer. Its lead product candidate is nirogacestat, an oral small molecule gamma secretase inhibitor that is in Phase III clinical trial for the treatment of desmoid tumors. The company is also deve...

Get notified when there are updates to the investment portfolio of Prelude Capital Management, LLC, based on Form 13F filings with the SEC.

Stay updated on Prelude Capital Management, LLC with notifications on news.